Assessing LAG-3 & PD-1 inhibition with fianlimab & cemiplimab in advanced melanoma

Meredith McKean, MD, Sarah Cannon Research Institute, Nashville, TN, explores the 24-month follow-up results from a Phase I study (NCT03005782) of fianlimab, a LAG-3 inhibitor plus cemiplimab, a PD-1 inhibitor, in patients with advanced melanoma. Efficacy was consistent across PD-L1 and LAG-3 subgroups, and safety was comparable to PD-1 monotherapy, confirming the durable clinical benefit and manageable safety profile of this combination therapy. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.